Bone Abstracts

Objective: To explore the characterization and risk factors of acute-phase response (APR) following a first-dose administration of 5 mg zoledronic acid for treatment of osteoporosis.

Method: We conducted clinical data of the zoledronic acid users for treatment of osteoporosis in Department of Endocrinology, West China Hospital, Sichuan University from January 2009 to November 2012.

Results: A total of 178 patients were eligible for inclusion in the study, of which 108 patients has experienced the APR. 80 (45%)patients developed fever, 14 (9.6%) chills, 48 (27%) musculoskeletal pain, 19 (10.7%) gastrointestinal symptoms, 10 (5.6%)headache and dizziness, 7 (3.9%)palpitation,and 3 (1.7%) rash. APR was more common in patients with higher baseline tartrate-resistant acid phosphatase 5b (TRACP-5b) and new-onset vertebral compression fractures (new-onset VCF). Stepwise logistic regression showed that the odds ratio (OR) to have APR in higher baseline TRACP-5b and new VCF was 3.3 and 2.5 respectively.

Conclusion: Patients with higher baseline TRACP-5b and new-onset VCF are more frequency in development of APR, which is worth to pay more attention to these patients.

Key words: Zoledronic acid, Acute-phase response, Osteoporosis.